Lomerizine Dihydrochloride
Cat.No:IL1240 Solarbio
CAS:101477-54-7
Molecular Formula:C27H32Cl2F2N2O3
Molecular Weight:541.46
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Solid
Qty:
Size:
{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Membrane Transporter & Ion Channel > Lomerizine DihydrochlorideCAS:101477-54-7
Molecular Formula:C27H32Cl2F2N2O3
Molecular Weight:541.46
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Solid
Qty:
Size:
| CAS | 101477-54-7 |
| Name | Lomerizine Dihydrochloride |
| Molecular Formula | C27H32Cl2F2N2O3 |
| Molecular Weight | 541.46 |
| Solubility | Soluble in DMSO(Need ultrasonic) |
| Purity | ≥98% |
| Appearance | Solid |
| Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
| MDL | MFCD01703867 |
| SMILES | COC1=C(C(=C(C=C1)CN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)OC)OC.Cl.Cl |
| InChIKey | LOGVKVSFYBBUAJ-UHFFFAOYSA-N |
| InChI | InChI=1S/C27H30F2N2O3.2ClH/c1-32-24-13-8-21(26(33-2)27(24)34-3)18-30-14-16-31(17-15-30)25(19-4-9-22(28)10-5-19)20-6-11-23(29)12-7-20;;/h4-13,25H,14-18H2,1-3H3;2*1H |
| PubChem CID | 122125 |
| Target Point | Calcium Channel |
| Passage | Membrane Transporter&Ion Channel;Neuronal Signaling |
| Background | It is a dual L-type and T-type voltage-gated calcium channel antagonist. |
| Biological Activity | Lomerizine dihydrochloride is an antagonist of L- and T-type voltagegated calcium channels.[1-4] |
| Data Literature Source | [1]. Tran LT,et al. The voltage-gated calcium channel blocker Lomerizine is neuroprotective in motor neurons expressing mutant SOD1,but not TDP-43. J Neurochem. 2014 Aug;130(3):455-66. [2]. Zhu HJ,et al. [Reversal of multidrug resistance by Lomerizine in K562/ADM cells]. Yao Xue Xue Bao. 2004 May;39(5):333-7. [3]. Nakamura-Yanagidaira T,et al. Development of spontaneous neuropathy in NF-κBp50-deficient mice by calcineurin-signal involving impaired NF-κB activation. Mol Vis. 2011;17:2157-70. [4]. Shimazawa M,et al. Effects of Ca2+ channel blockers on cortical hypoperfusion and expression of c-Fos-like immunoreactivity after cortical spreading depression in rats. Br J Pharmacol. 1995 Aug;115(8):1359-68. |
| Unit | Bottle |
| Specification | 100mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download